Takeda is setting up a new joint venture in Japan to extend its global clinical development partnership with PRA, as part of an ongoing R&D overhaul.
Following its unveiling of a major global R&D overhaul last year, Takeda Pharmaceutical Co. Ltd. is further strengthening its alliance with contract research organization PRA Health Sciences Inc. through the planned formation of a new joint venture in Japan.
The equally held operation will provide clinical development and pharmacovigilance services in the country to Takeda, managing a broad portfolio of studies across the Phase I to IV (postmarketing) spectrum, and
An ‘historic economic prosperity deal’ does not include the sector.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
An ‘historic economic prosperity deal’ does not include the sector.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
